Because SIRT7 activity strongly increased Pax5 levels in B cell progenitors, human B-ALL samples and cell lines, we propose that developing SIRT7-activating compounds to stimulate Pax5 functions may provide a basis for leukemia therapies. This evidence concerns the gene PAX5 and precursor B-cell acute lymphoblastic leukemia.